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Cystic fibrosis (CF) is a multisystem 
disease, affecting many organs including 
the liver, intestines, respiratory and 
reproductive tracts, bone, heart, spleen, 
gall bladder, and pancreas (Table 1) [1]. 
It is the pulmonary manifestations that 
account for significant morbidity and 
mortality in patients with CF [2]. The CF 
transmembrane conductance regulator 
(CFTR) protein is central to CF disease. 
CFTR is a cyclic adenosine monophosphate-
activated, adenosine triphosphate-binding 
cassette transporter protein (Figure 1). 
Expressed in submucosal glands and the 
apical membranes of epithelial cells in the 
liver, pancreas, intestines, reproductive tract, 
and lungs, the CFTR normally functions as 
a chloride channel. Individuals with CF have 
mutations in the CFTR gene. More than 
1800 CFTR mutations have been identified 
to date. A subgroup of CFTR mutations are 
disease-causing and, as CF is an autosomal 
recessive disease, two alleles with such 
mutations are required to cause the disease. 
CFTR mutations can be grouped into six 
classes (I–VI) depending on whether they 
affect the expression, processing, or activity 
of CFTR, or a combination of these [3,4]. 
For example, the class III glycine to aspartic 
acid mutation at codon 551 (G551D) leads to 
a CFTR channel defect, whereas the class II 
deletion of phenylalanine mutation at codon 
508 (ΔF508) results in a CFTR protein 
that is aberrantly folded and defectively 
processed in the endoplasmic reticulum. 
CFTR alleles with the ΔF508 mutation 
account for approximately 70% of mutated 
CFTR alleles worldwide; 64% of the Irish CF 
population is homozygous for ΔF508, while 
94% carry the ΔF508 mutation on at least 
one chromosome [5]. 
Gender differences in CF
Gender dichotomy is recognized in CF 
disease, with female patients having poorer 
survival, worse lung function, and earlier 
colonization with Pseudomonas aeruginosa 
[6–17]. The lack of an explanation for this 
disparity coupled with a narrowing of the 
gender gap in recent times has sparked 
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debate about whether such a gap ever existed, 
or whether the improvements observed can 
be explained by therapeutic advances or 
a greater compliance with therapy among 
female patients. Interestingly, Masterson 
et al. studied adherence to infection 
control guidelines and medical therapy 
in a cohort of patients with CF, and found 
that although age-related differences exist, 
gender is not a significant factor associated 
with treatment adherence [18]. However, 
it is clear that female gender is a negative 
prognostic factor in CF, a finding that has 
been demonstrated in several countries, 
registries, and CF care centers. Two recent 
studies found no difference in survival 
between genders [19,20]; however, Olsen et 
al. did acknowledge that female patients 
with CF are at a higher risk of P aeruginosa 
and Burkholderia spp. colonization, require 
more intensive treatment with antibiotics, 
and have a greater rate of hospitalization 
compared with male patients [19]. It was 
noted in that study that a gender gap may 
appear after adolescence, which is the time-
frame within which other published studies 
have shown such differences to exist [20]. 
Studies examining the major female hormone 
17β-estradiol (an estrogen; E2) and its effect 
on infectious, inflammatory, and immune 
consequences in the CF airway are ongoing 
in an attempt to explain these fundamental 
gender differences. The next decade may, 
in fact, provide explanations to these long-
acknowledged observations in CF disease. 
Clinical management of CF
CF is diagnosed by the presence of relevant 
clinical symptoms in at least one organ 
system together with evidence of CFTR 
dysfunction. The latter is satisfied by 
elevated sweat chloride levels measured on 
two separate occasions (>60 mmol/L), the 
identification of two disease-causing CFTR 
mutations by DNA analysis, and abnormal 
nasal potential difference (NPD) or 
intestinal current measurements (ICM) [21].
Clinical disease is described as 
“classic”, with patients having multi-
system involvement, or “non-classic”, with 
Table 1. organ involvement in cystic fibrosis.
Nose and sinuses Nasal polyps
sinusitis
Lungs allergic bronchopulmonary 
aspergillosis
atelectasis
bronchiectasis
bronchiolitis
bronchitis
Cor pulmonale
Hemoptysis
mucoid impaction of the bronchi
Pneumonia
Pneumothorax
reactive airway disease
respiratory failure
Heart Pulmonary artery dilation
right ventricular hypertrophy
Liver Hepatic steatosis
Portal hypertension
Stomach Gastroesophageal reflux 
disease
Spleen Hypersplenism
Gallbladder biliary cirrhosis
Cholelithiasis
Neonatal obstructive jaundice
Pancreas diabetes
insulin deficiency
Pancreatitis
symptomatic hyperglycemia
Intestines appendicitis
distal intestinal obstruction 
syndrome
Fibrosing colonopathy 
(strictures)
inguinal hernia
intestinal atresia
intussusception
meconium ileus
meconium peritonitis
rectal prolapse
Volvulus
Reproductive  
organs
amenorrhea
delayed puberty
infertility (aspermia, absence  
of vas deferens)
Bone arthritis
Clubbing
Hypertrophic osteoarthropathy
osteoporosis
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patients in this group – despite fulfilling 
the diagnostic criteria for CF – having 
intermediate sweat chloride concentrations 
(40–60 mmol/L) coupled with disease 
limited to a single organ system. Features of 
the disease originate from the basic CFTR 
defect of impaired chloride ion transport and 
epithelial sodium channel-driven sodium 
hyperabsorption leading to thick, viscid 
luminal mucus and a high salt content in 
sweat. Great strides have been made in CF 
treatment over the last two decades, and 
this is attributable to improvements in 
clinical trials and a better understanding 
of disease pathophysiology at a molecular 
level. What remains central to the effective 
management of CF is a multidisciplinary 
approach to patient care. Although the 
disease is characterized by gastrointestinal, 
respiratory, and other organ involvement, the 
remainder of this review focuses only on the 
pulmonary manifestations of CF.
Respiratory disease in CF
The pulmonary manifestations of CF are 
responsible for significant morbidity and 
mortality and can encompass a spectrum of 
symptoms ranging from persistent productive 
cough associated with mucopurulent sputum, 
to chronic rhinosinusitis with nasal polyposis. 
Advanced irreversible bronchiectasis is 
observed with disease progression. The 
airways become colonized with a range of 
microorganisms including Staphylococcus 
aureus and Haemophilus influenzae early in 
life, followed by P aeruginosa and Burkholderia 
spp., amongst others, in older patients.
Antibiotics are the mainstay in the 
management of infective pulmonary CF and 
can be used to suppress and/or treat infection. 
The route of administration may vary and, 
to a large extent, depends upon the clinical 
scenario and microorganism sensitivities; 
for example, intravenous antibiotics may 
be combined with inhaled antibiotics in 
Figure 1. schematic illustration of the CFtr. CFtr is a camP-activated atP-binding cassette protein 
that functions as a chloride channel. it has two msds that form the channel. activation occurs via the  
r domain, facilitating atP binding to the two Nbds, allowing the channel to open and close and 
transport chloride ions.
atP: adenosine triphosphate; camP: cyclic adenosine monophosphate; CFtr: cystic fibrosis transmembrane conductance regulator;  
msd: membrane spanning domain; Nbd: nucleotide binding domain; r: regulatory.
MSD1 MSD2
NH2
COOH
RNBD1 NBD2
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the hospital setting. The largest proportion 
of antibiotics used in CF management is 
prescribed for acute infective exacerbations. 
An exacerbation is determined by worsening 
clinical symptoms and parameters of lung 
function associated with increased or 
changing sputum production or purulence. 
In the context of an infective 
exacerbation, oral antibiotics can be 
appropriate if the exacerbation is mild and 
the organisms are fully sensitive to the 
antibiotics used. Oral azithromycin can also 
be prescribed on alternate days in patients 
chronically colonized with P aeruginosa. 
Belonging to the macrolide group of antibiotic 
compounds, azithromycin possesses anti-
infective, immunomodulatory, and anti-
inflammatory properties. Although not all 
proven in the setting of CF, these multiple 
properties have prompted some CF centers 
to use azithromycin empirically in patients 
with deteriorating lung function and clinical 
evidence of airway inflammation. In addition 
to azithromycin use in CF patients who are 
chronically colonized with P aeruginosa, a 
recent clinical trial was conducted in patients 
not colonized by P aeruginosa [22]. Although 
there was no effect on pulmonary function, 
a significant delay in the interval between 
exacerbations was found.
Hospital- or home-based intravenous 
antibiotic therapy is reserved for severe 
exacerbations, where bacterial resistance 
to oral therapy has been identified and/
or a failure of oral antibiotics to resolve 
infection has occurred. In the setting of 
an exacerbation in a patient chronically 
colonized with P aeruginosa, at least two 
agents (one with broad Gram-negative and 
anti-pseudomonal cover) are selected and 
administered for ≥10 days and up to 4 weeks, 
or longer if necessary. Antibiotic choices 
are directed by sputum culture and in vitro 
susceptibility testing results, and, in the 
majority of cases, include one or more of the 
following: tobramycin, colistin, ceftazidime, 
piperacillin plus tazobactam, meropenem, 
and aztreonam. If methicillin-resistant 
S aureus is cultured, vancomycin or linezolid 
are employed; if an isolated P aeruginosa 
strain shows resistance to tobramycin, 
amikacin remains an option. 
In addition to their occasional use 
in the setting of an acute exacerbation, 
nebulized antibiotics are generally reserved 
for the suppression of infection. Tobramycin 
improves both forced expiratory volume in 1 s 
(FEV1) and reduces exacerbations when used 
for chronic P aeruginosa colonization in a 
“1 month on, 1 month off” regimen [23]. The 
monobactam aztreonam lysine has shown 
similar clinical benefit to tobramycin in 
chronic P aeruginosa colonization [24], and 
trials are underway comparing the two. An 
alternative choice, usually reserved for patients 
intolerant to or performing poorly with 
tobramycin, is colomycin. Although effective, 
it appears to be inferior to tobramycin [25], 
while no comparisons with aztreonam have 
been made to date. 
Agents that promote airway clearance 
are used for the respiratory management of 
CF. Dornase alfa reduces sputum viscosity, 
improves FEV1, and reduces hospitalization 
time [26], while hypertonic saline hydrates 
inspissated mucus by drawing water 
into the airway lumen. This can help to 
reduce pulmonary exacerbations [27]. 
Bronchodilators such as β2 agonists or anti-
cholinergics are further therapeutic options 
that may be employed in CF patients with 
varying disease severities. 
In addition to macrolides, ibuprofen 
has been shown to prevent FEV1 decline 
with limited side-effects in CF; however, 
it is uncommonly prescribed because of 
concerns about the high doses required 
and its long-term impact on renal function 
[28]. Other critical backbones in the 
respiratory care of patients with CF include 
chest physiotherapy, exercise regimens, 
and routine prophylactic influenza and 
pneumococcal vaccinations. 
The development of new therapeutic 
approaches for CF continues at a rapid 
pace that is best demonstrated by the large 
number of potential treatments under 
investigation according to the US CF 
foundation pipeline [29]; these include 
antioxidants, protease inhibitors, and anti-
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inflammatory therapies. Targeting the 
basic genetic defect with CFTR potentiators 
offers significant promise. VX-770 is an 
agent that increases the activity of surface 
CFTR channels in patients with the G551D 
mutation. In Phase II clinical trials, VX-770 
was well tolerated and showed improvements 
in NPDs, sweat chloride levels, and 
pulmonary function over a 2-week period 
[30]. With such encouraging early data, 
the results of Phase III trials are eagerly 
anticipated, as is the development of similar 
compounds aimed at the correction of other 
and more common gene variants seen in CF. 
Pulmonary inflammation in CF
Pulmonary infection and inflammation in 
CF are multifaceted processes. Defective 
chloride ion conductance by airway epithelial 
cells causes a reduction in the airway surface 
liquid (ASL) height, an increase in mucus 
expression and viscosity that facilitates 
chronic microbial colonization, and an 
influx of activated neutrophils (Figure 2). 
Imbalances in the normal protease–
antiprotease balance occur because of the 
presence of excess neutrophil- and bacterial-
derived proteases within the CF lung, which 
can interfere with normal innate immune 
responses [31]. Pulmonary inflammation 
in CF is also mediated by proinflammatory 
molecules such as ceramide, chemotactic 
tripeptides [32], C5a, and the leukotriene 
LTB4, which together contribute to the highly 
proinflammatory milieu in the CF lung. 
Because of the high numbers of infiltrating 
neutrophils in the CF lung and their ability 
to release reactive oxidant species, the redox 
balance within the CF lung is also altered. 
This is further exaggerated as a result of 
reduced glutathione levels on the respiratory 
epithelial surface in CF [33], and together 
these imbalances lead to oxidative damage. 
Additional idiosyncratic factors such as CFTR 
Figure 2. Features of CF airway epithelium. defective CFtr function leads to reduced and dehydrated 
asl on the airway epithelium. increased mucus production facilitates microbial colonization with 
Pseudomonas spp. and other species. PamPs activate tlr signaling in bronchial epithelial cells to 
increase expression of the neutrophil chemokine il-8, causing neutrophils to be recruited into the lumen 
of the lung. these neutrophils can secrete factors such as neutrophil elastase that further activate the 
airway epithelium leading to a vicious cycle of inflammation.
asl: airway surface liquid; CF: cystic fibrosis; CFtr: cystic fibrosis transmembrane conductance regulator; il-8: interleukin-8;  
PamPs: pathogen-associated molecular patterns; tlr: toll-like receptor.
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genotype, gender, Pseudomonas spp. mucoidy, 
and co-colonization with Staphylococcus spp., 
Burkholderia spp., or anaerobic bacterial 
species are further contributory factors. These 
protean factors coupled with the consequence 
of treatment regimens and exacerbation 
history all combine to generate a disease 
requiring very specific personalized medical 
treatment for each CF case.
Pulmonary innate immune mechanisms 
include, amongst others, the mucociliary 
escalator, proteases, antiproteases, anti-
microbials, and pattern recognition receptors. 
The purpose of cilia is to sweep mucus and 
dirt out of the lungs. The luminal surface of 
the airway is coated with mucus, which acts 
as a protective barrier against toxins and 
pathogens, and normally clears particles and 
infectious agents from the airways via the 
mucociliary escalator. Mucus is composed of 
water, ions, proteins, lipids, and polymeric 
glycoproteins called mucins. To date, 19 
human mucin genes have been identified. 
The most important airway mucins are the 
secreted mucins, Muc5AC and Muc5B, which 
are produced by goblet cells of the superficial 
airway epithelium. Their expression is 
increased in the CF lung, and the overall 
composition of CF mucus is altered as a result 
of an increased content of macromolecules 
such as DNA, filamentous actin, lipids, and 
proteoglycans. Together these contribute to 
mucus plugging within the CF lung [34,35]. 
Toll-like receptors (TLRs) are a family 
of pattern recognition receptors that act as 
a first line of defense in the innate immune 
response. Expressed by immune and 
epithelial cells within the lung and belonging 
to the TLR/interleukin-1 (IL-1) receptor 
superfamily, TLRs can recognize and respond 
to conserved molecular patterns in microbial 
factors and endogenous danger signals 
(Table 2) [36]. These pathogen- and danger-
associated molecular patterns (PAMPs 
and DAMPs, respectively) provide rapid 
and potent stimulation of innate immune 
signaling pathways, which culminates in 
proinflammatory cytokine expression and 
communication with the adaptive immune 
system to effectively eliminate invading 
pathogens and coordinate the ensuing 
inflammatory process. The CF lung is a 
PAMP- and DAMP-rich milieu, represented 
by microbial-derived factors (bacterial, 
viral, and fungal) and neutrophil elastase, 
respectively. Current understanding accepts 
that the chronic inflammatory phenotype 
evident in CF airway epithelial cells is due, in 
large part, to activation of TLRs [37]. 
The neutrophil-dominated phenotype 
of the CF lung predisposes to a variety of 
phenomena. Neutrophil-derived oxidants 
and proteases cause derangement in the CF 
lung and overwhelm the normal antiprotease 
defenses of the respiratory epithelial surface. 
Neutrophil elastase is the major protease 
released by neutrophils in the CF lung, 
where it has significant effects [38]. Not only 
does it upregulate the expression of other 
proteases including cysteinyl cathepsins 
and metalloproteases, but it also inactivates 
the serine antiproteases elafin and secretory 
leukoprotease inhibitor (SLPI), and interferes 
with their immunomodulatory and anti-
inflammatory properties [38,39]. Along with 
other pulmonary proteases, neutrophil elastase 
can generate bioactive molecules from proteins 
such as collagen and, in concert with the 
other principal elastolytic proteases present 
in the CF lung (proteinase-3, macrophage-
derived metalloelastases, and elastolytic 
proteases expressed by P aeruginosa), it can 
promote the secretion of mucus and degrade 
surfactant proteins and antimicrobials. 
Neutrophil elastase can also directly injure 
epithelial cells and reduce ciliary beat 
frequency, cleave complement components and 
immunoglobulins, and interfere with effective 
neutrophil killing of microbes. In the CF lung, 
neutrophil elastase-induced activation of TLR 
signaling is mediated via epidermal growth 
factor receptor (EGFR)-ligand generation and 
EGFR activation [40].
CF displays wide variability in its 
clinical features and mortality. Correlations 
between the CFTR genotype and disease 
manifestations and progression are weak 
overall, thus highlighting that other factors 
are important. Indeed, genetic modifiers 
have been reported to play a substantial role 
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in determining FEV1. The most promising 
candidate modifier genes for CF include IL-8, 
mannose-binding lectin, transforming growth 
factor-β1, interferon-related developmental 
regulator-1, and endothelin receptor type A 
(reviewed in [41]), while the serpin peptidase 
inhibitor-A1 Z allele is a risk factor for liver 
disease in patients with CF [42]. 
Female gender differences in CF
Female gender differences in CF may be 
related to circulating female hormones such 
as estrogens. Estrogens are the primary 
female sex hormone and have a fundamental 
role during the female menstrual cycle. 
Estrogens circulate in three natural forms: 
estrone (E1), estradiol (E2), and estriol 
(E3), with E2 being the predominant and 
most active form in non-pregnant female 
individuals. Despite being less potently 
estrogenic, E1 has importance during the 
menopause, while E3 assumes its core 
function during pregnancy. 
Estrogen receptors and physiology
Following diffusion across the lipid cell 
membrane, E2 binds to its major cytosolic 
receptors, the transcription factors estrogen 
receptor-α (ERα) and -β (ERβ). Both ER 
subtypes are composed of five domains (A–F), 
each possessing distinct functions (Figure 3) 
[43]. Domains E and F bind estrogen 
and facilitate receptor dimerization and 
interaction with coregulators. Both receptors 
can localize to the nucleus as a result of 
nuclear localization motifs in domain D. 
Once in the nucleus, ERs bind to DNA via 
domain C and promote gene transcription 
Table 2. PamPs, damPs, and tlr signaling. a selection of the major PamPs and damPs that activate 
the different tlrs and their adaptor proteins, through which signaling cascades are initiated leading 
to transcription factor activation.
PAMP DAMP TLR Adaptor 
protein
Transcription 
factor
diacylated 
lipopeptides
β-defensin-3 tlr1/2 myd88, mal NFκb
triacylated 
lipopeptides
TLR2/6 myd88, mal NFκb
serum amyloid a, neutrophil elastase, 
HSP60,	HSP70,	GP96,	surfactant	A	and	D,	
eosinophil-derived neurotoxin, biglycan, 
versican, hyaluronic acid, HmbG1, anti-
phospholipid antibodies
tlr2
double-stranded 
rNa
mrNa tlr3 triF irFs, NFκb
lPs biclycan, heparan sulphate, hyaluronic 
acid, neutrophil elastase, serum amyloid a, 
oxidized ldl, fibronectin eda, fibrinogen, 
tenascin-C, lactoferrin, β-defensin-2, 
saturated fatty acids, HmGb1, HsP22, 
HSP60,	HSP70,	HSP72,	GP96,	lactoferrin
tlr4 myd88, mal, 
triF, tram
NFκb, irFs
Flagellin tlr5 myd88 NFκb
Guanosine- and 
uridine-rich single-
stranded rNa
anti-phospholipid antibodies tlr7/8 myd88 irFs, NFκb
unmethylated 
CpG dinuceotides, 
hemozoin
igG-chromatin complexes tlr9 myd88 irFs, NFκb
CpG: cytosine–guanine; damPs: danger-associated molecular patterns; GP: glycoprotein; HmGb1: high-mobility group protein-b1; HsP: 
heat-shock protein; igG: immunoglobulin G; irFs: interferon regulatory factors; mal: myd88-adapter-like; myd88: myeloid differentiation 
primary response protein-88; NFκb: nuclear factor-κb; ldl: low-density lipoprotein; lPs: lipopolysaccharide; PamPs: pathogen-associated 
molecular patterns; tram: tir-domain-containing adapter molecule; triF: tir-domain-containing adapter inducing interferon-β; tlr: 
toll-like receptor.
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via their transcriptional activation domains 
in the A/B region. While E2 mediated 
changes in gene expression take several 
hours (so-called “genomic” effects), E2 can 
also exert rapid influences upon cells within 
seconds mediated by ERα and ERβ and by 
the genetically and structurally unrelated 
G-coupled protein receptor-30 [44]. With 
respect to genomic signaling, ERs modulate 
gene expression by hormone–receptor 
complex interaction with estrogen response 
elements in the promoter or enhancer region 
of target genes. Interestingly ER homo- or 
heterodimers can activate or inhibit gene 
expression depending on cell type [45]. As 
both ERs are targets for post-translational 
modifications including phosphorylation, 
acetylation, nitrosylation, and ubiquitination, 
their transcriptional activity can be subtly 
modulated in a context-specific manner.
Estrogen receptor localization  
and function
The distribution of the ERs varies throughout 
the body. In some organs, both receptors are 
equally expressed, whereas, in others, one 
subtype predominates (Table 3) [43]. ERα 
predominates in the reproductive tissues, 
bone, liver, and kidneys, while ERβ is more 
abundant in the colon, bladder, and lung. The 
effects of E2 after exposure are plentiful and 
extend beyond its well-described reproductive 
role. For example, it regulates carbohydrate 
and lipid metabolism, skeletal homeostasis, 
and functional cerebral integrity. Its role 
within the pulmonary environment is a 
subject of intense ongoing investigation 
by our group and others, particularly in 
the context of chronic inflammatory lung 
diseases such as CF [46]. The complex 
role of estrogens in inflammation is best 
summarized by its “inflammatory paradox”: 
inhibitory and anti-inflammatory in some 
contexts versus proinflammatory at other 
times (e.g. autoimmunity) [47]. Estrogenic 
effects in a given environment are dependent 
on a number of criteria including the immune 
stimulus, variability of ER expression, target 
organ microenvironment, the cell type, the 
timing and concentration of E2 exposure, and 
intracellular metabolism.
As estrogen plays an important (albeit 
complex) role in inflammation, it is not 
surprising that epidemiological and 
immunological evidence suggests a role for 
estrogen in the cause and course of chronic 
inflammatory diseases such as CF. Increased 
expression of ERβ has been linked to 
oxidative stress, hypoxia, and trauma [48–50]. 
We have shown that ERβ is also dominant 
over ERα in CF bronchial epithelium. Within 
this context, it makes sense that ERβ is the 
predominant ER within the chronically 
inflamed CF airway [46]. 
Contrasting roles of E2 in CF  
and asthma
Our group has demonstrated that, in the 
female CF airway, high circulating E2 levels 
confer TLR hyporesponsiveness to a range of 
bacterial agonists manifested by an inhibition 
of IL-8 release. The mechanism by which 
this phenomenon occurs is through ERβ-
mediated upregulation of SLPI, a serine 
antiprotease expressed in the respiratory 
tract, which also has antimicrobial, anti-
Figure 3. er domains. erα and erβ receptors have six structural domains (a–F) each possessing 
functional relevance. 
er: estrogen receptor.
AF-1 region AF-2 region
ERα 1 595CA/B E/FD
ERβ 1 530CA/B E/FD
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inflammatory, and immunomodulatory 
properties [46]. SLPI competitively inhibits 
nuclear factor-κB (NF-κB) p65 subunit 
binding to DNA, thereby inhibiting the 
transcription of NF-κB-regulated genes such 
as IL-8 (Figure 4) [51]. Additionally, NF-κB 
has been shown to interact with ER pathways 
in non-CF environments. For instance, in 
monocytic cells and macrophages, E2 can 
block lipopolysaccharide-induced NF-κB 
activity [52]. As E2 can play an anti-
inflammatory role in both CF and non-CF 
contexts, we hypothesized that, although 
uncontrolled chronic inflammation is 
damaging over a prolonged time period, 
surges of acute inflammation in the setting 
of an acute bacterial exacerbation in CF may, 
in fact, provide protection. This “protective” 
acute inflammatory burst is compromised 
during E2 exposure in female patients 
with CF and, taken with the fact that E2 
compromises the ASL, high circulating E2 
levels in female patients can confer both 
a higher initial risk of infection and a 
subsequent blunted response to such infection 
[53]. Whether similar events occur during 
viral exacerbations remains to be determined.
While the hypothesis described above 
suggests that estrogen is one of the important 
factors involved in the gender gap in CF 
disease, several other gender-specific co-
variables may also play roles. Nonetheless, an 
E2-mediated hyporesponsive inflammatory 
response helps explain why some anti-
inflammatory agents in CF such as the 
LTB4 antagonist have been unsuccessful 
during clinical trials, with an increased 
infection rate seen in the treatment arm, 
resulting in premature trial termination 
(ClinicalTrials.gov identifier: NCT00060801) 
[54]. Conversely, improvements in pulmonary 
inflammation have been demonstrated with 
long-term high-dose ibuprofen in milder 
disease; however, the underlying mechanisms 
for these effects in CF remain to be further 
elucidated [28]. Evidently, the context 
and timing of administration of an anti-
inflammatory agent requires careful thought.
Asthma is another chronic airway-
based disease in which exacerbations have 
been shown to follow hormonal variations 
in female patients. A role for E2 in the 
pathophysiology of asthma stems from 
work illustrating an increased risk of the 
condition in post-menopausal women 
using hormone replacement therapy [55], 
and cyclical changes in airflow and gas 
transfer over the menstrual cycle in affected 
patients [56]. However, in contrast to CF, 
E2 exposure appears to have a protective 
effect on the asthmatic airway; female 
patients with asthma experience increased 
exacerbations, hospitalizations, and reduced 
pulmonary function when E2 levels are low. 
An explanation for these findings may lie in 
the fact that E2 relaxes airway smooth muscle 
via its rapid effects on intracellular calcium 
[57]. In addition, during natural menstrual 
cycles, exhaled nitric oxide, a marker of 
airway inflammation, is markedly reduced, 
reiterating the anti-inflammatory, protective 
role of E2 in asthma [58]. Interestingly, these 
effects were abolished with oral contraceptive 
(OCP) use and support the concept of 
“catamenial asthma” (i.e. exacerbations 
during menstruation, a time of low E2). It 
would be interesting to know the effect of 
OCP use in the context of CF lung disease. 
In the asthmatic lung where the ASL is not 
compromised, the anti-inflammatory effect 
of high E2 levels may protect and relax the 
airway and prevent exacerbations. In CF, the 
already diminished ASL undergoes further 
dehydration upon E2 exposure, increasing 
the risk of infection while also being less 
well equipped to cope with infection because 
of TLR hyporesponsiveness.
Table 3. er distribution. ers are distributed 
throughout the body however predominance of 
one over the other may be found at particular 
sites. the major estrogen receptor within the 
lung is erβ.
ER Organ
erα CNs, CV system, breast, liver, urogenital 
tract, bone
erβ CNs, CV system, lung, breast, Gi tract, 
urogenital tract, bone
CNs: central nervous system; CV: cardiovascular; er: estrogen 
receptor; Gi: gastrointestinal.
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Figure 4. the effect of e2 within the CF airway. A: in states of low circulating e2, microbial agonists 
stimulate tlrs resulting in the activation of NF-κb and subsequent release of the neutrophil chemokine 
il-8 attracting neutrophils to the airway with the aim of bacterial clearance; B: during high circulating 
e2 levels and following infection and exacerbation, a blunted response to microbial agonists occurs 
resulting in diminished luminal il-8 and a hyporesponsive immune state due to the upregulation of slPi 
that inhibits NF-κb binding to dNa.
e2: 17β-estradiol; erβ: estrogen receptor-β; il-8: interleukin-8; NF-κb: nuclear factor-κb; slPi: secretory leukoprotease inhibitor;  
tlr: toll-like receptor.
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Neutrophils
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Unraveling further effects of E2 on airway 
epithelial and immune cell physiology 
will lead to a greater understanding of 
how hormonal control can impact on 
the pulmonary manifestations of CF. 
Conceivably, this may lead to new treatment 
regimens to address the CF gender gap.
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